Climb Bio Inc (CLYM) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Climb Bio Inc stock (CLYM) is currently trading at $6.68. Analyst consensus price target for CLYM is $14.30. WallStSmart rates CLYM as Sell.
- CLYM PE ratio analysis and historical PE chart
- CLYM PS ratio (Price-to-Sales) history and trend
- CLYM intrinsic value — DCF, Graham Number, EPV models
- CLYM stock price prediction 2025 2026 2027 2028 2029 2030
- CLYM fair value vs current price
- CLYM insider transactions and insider buying
- Is CLYM undervalued or overvalued?
- Climb Bio Inc financial analysis — revenue, earnings, cash flow
- CLYM Piotroski F-Score and Altman Z-Score
- CLYM analyst price target and Smart Rating
Climb Bio Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Climb Bio Inc (CLYM) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around return on equity. Significant fundamental concerns warrant caution or avoidance.
Climb Bio Inc (CLYM) Key Strengths (2)
76.18% of shares held by major funds and institutions
Trading at 1.82x book value, attractively priced
Supporting Valuation Data
Climb Bio Inc (CLYM) Areas to Watch (2)
Company is destroying shareholder value
Small-cap company with higher risk but more growth potential
Climb Bio Inc (CLYM) Detailed Analysis Report
Overall Assessment
This company scores 21/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 2 register as strengths (avg 9.0/10) while 2 fall into concern territory (avg 2.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Price/Book. Valuation metrics including Price/Book (1.82) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Market Cap. Profitability pressure is visible in Return on Equity at -32.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -32.20% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Market Cap are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CLYM Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
WallStSmart Analysis Synopsis
Data-driven financial summary for Climb Bio Inc (CLYM) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Climb Bio Inc operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Free cash flow is -16M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Climb Bio Inc.
Bottom Line
Climb Bio Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:25:24 AM
About Climb Bio Inc(CLYM)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. The company is headquartered in Wilmington, Delaware.